SEVELAMER HYDROCHLORIDE SANOFI sevelamer hydrochloride 800 mg tablet bottle Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sevelamer hydrochloride sanofi sevelamer hydrochloride 800 mg tablet bottle

sanofi-aventis australia pty ltd - sevelamer hydrochloride -

SEVELAMER HYDROCHLORIDE SANOFI sevelamer hydrochloride 400 mg tablet bottle Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sevelamer hydrochloride sanofi sevelamer hydrochloride 400 mg tablet bottle

sanofi-aventis australia pty ltd - sevelamer hydrochloride -

SEVELAMER CARBONATE SANOFI sevelamer carbonate 2.4 g powder for oral suspension sachet Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sevelamer carbonate sanofi sevelamer carbonate 2.4 g powder for oral suspension sachet

sanofi-aventis australia pty ltd - sevelamer carbonate -

SEVELAMER CARBONATE SANOFI sevelamer carbonate 800 mg tablet bottle Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sevelamer carbonate sanofi sevelamer carbonate 800 mg tablet bottle

sanofi-aventis australia pty ltd - sevelamer carbonate -

SEVELAMER CARBONATE SANOFI sevelamer carbonate 1.6 g powder for oral suspension sachet Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sevelamer carbonate sanofi sevelamer carbonate 1.6 g powder for oral suspension sachet

sanofi-aventis australia pty ltd - sevelamer carbonate -

CLOLAR- clofarabine injection Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

clolar- clofarabine injection

sanofi-aventis u.s. llc - clofarabine (unii: 762rdy0y2h) (clofarabine - unii:762rdy0y2h) - clofarabine 1 mg in 1 ml - clolar® (clofarabine) injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens. this indication is based upon response rate. there are no trials verifying an improvement in disease-related symptoms or increased survival with clolar. none pregnancy category d clolar (clofarabine) may cause fetal harm when administered to a pregnant woman. clofarabine was teratogenic in rats and rabbits. developmental toxicity (reduced fetal body weight and increased post-implantation loss) and increased incidences of malformations and variations (gross external, soft tissue, skeletal and retarded ossification) were observed in rats receiving 54 mg/m2 /day (approximately equivalent to the recommended clinical dose on a mg/m2 basis), and in rabbits receiving 12 mg/m2 /day (approximately 23% of the recommended clinical dose on a mg/m2 basis). there are no adequate and well-controlled studies in pregnant women usin

IRBESARTAN HCT WINTHROP 300/25 irbesartan 300mg and hydrochlorothiazide 25mg film-coated tablet blister pack Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

irbesartan hct winthrop 300/25 irbesartan 300mg and hydrochlorothiazide 25mg film-coated tablet blister pack

sanofi-aventis australia pty ltd - hydrochlorothiazide,irbesartan -

IRBESARTAN HCT WINTHROP 300/12.5 irbesartan 300 mg and hydrochlorothiazide 12.5 mg film-coated tablet blister pack Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

irbesartan hct winthrop 300/12.5 irbesartan 300 mg and hydrochlorothiazide 12.5 mg film-coated tablet blister pack

sanofi-aventis australia pty ltd - hydrochlorothiazide,irbesartan -

IRBESARTAN HCT WINTHROP 150/12.5 irbesartan 150 mg and hydrochlorothiazide 12.5 mg film-coated tablet blister pack Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

irbesartan hct winthrop 150/12.5 irbesartan 150 mg and hydrochlorothiazide 12.5 mg film-coated tablet blister pack

sanofi-aventis australia pty ltd - hydrochlorothiazide,irbesartan -

LIXISENATIDE SANOFI TREATMENT INITIATION PACK 10mcg (0.05 mg/mL) and 20 mcg (0.1) mg/mL solution for injection injector pen Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

lixisenatide sanofi treatment initiation pack 10mcg (0.05 mg/ml) and 20 mcg (0.1) mg/ml solution for injection injector pen

sanofi-aventis australia pty ltd - lixisenatide -